12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Company News  |  Deals

MonoSol Rx, Vestiq deal

Vestiq acquired exclusive, U.S. rights to Zuplenz ondansetron oral soluble film from MonoSol. MonoSol received an undisclosed upfront payment and is eligible for double-digit royalties. Zuplenz is approved to prevent nausea and vomiting associated with radiotherapy and highly or moderately emetogenic cancer...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >